Sanofi Reports P-IIa (HS-OBTAIN) Trial Data of Brivekimig for Hidradenitis Suppurativa

Shots:Sanofi has reported the P-IIa (HS-OBTAIN) trial data assessing brivekimig (150mg, SC, Q2W) vs PBO in pts with mod. to sev. hidradenitis suppurativa, incl. biologic-naïve pts for 16 wks., followed by a 12wk. open-label period & an 8wk. safety follow-upAt 16wks., brivekimig achieved higher HiSCR50 median response rates of 67% vs 37%, with 54%…

ByRidhi RastogiSeptember 17, 2025

NEWS

Ethris Reports First Patient Dosing in P-IIa Trial of ETH47 for Asthma

Shots:Ethris has dosed the first pts in a P-IIa trial of ETH47 for asthma symptom reduction after rhinovirus challenge, building on P-I trial data, which showed strong respiratory tract activity, local IFNλ induction, antiviral gene activation, & no systemic exposureThe P-IIa trial will evaluate ETH47 vs PBO in ~50 adults with asthma who…

ByRidhi RastogiAugust 5, 2025

NEWS

Ascletis Pharma Reports First Patient Dosing with ASC30 in P-IIa Trial for Obese or Overweight Patients

Shots:Ascletis Pharma has dosed first participants with ASC30 (PO, QD) in its US P-IIa trial for obesity (BMI ≥30kg/m^2) or overweight pts (BMI ≥27kg/m^2 but <30kg/m^2) with ≥1 weight-related comorbidityTrial will assess 2 ASC30 formulations (tablets & tablets A1), with pts starting at 1mg & undergoing weekly titrations to maintenance doses of 20 or 40mg…

ByRidhi RastogiJuly 3, 2025

NEWS

Processa Pharmaceuticals and Intact Therapeutics Enter Binding Term Sheet for PCS12852 Licensing Deal

Shots:Processa & Intact have entered into a binding term sheet for granting Intact an exclusive option to license PCS12852 for gastroparesis & other GI motility disordersAs per the deal, Processa will receive a 3.5% equity in Intact at closing, $2.5M option fee, ~$20M in development & regulatory milestones, ~$432.5M in commercial milestones, &…

ByRidhi RastogiJune 18, 2025

NEWS

Skye Bioscience Enters a Formulation Development Agreement with Arecor Therapeutics for Nimacimab

Shots:Skye Bioscience has partnered with Arecor Therapeutics to develop a higher concentration formulation of Skye’s nimacimab, leveraging Arecor’s Arestat formulation platformAs per the deal, Skye will fund Arecor's development efforts, with the option to license rights of the new proprietary formulation & its intellectual property for further development & commercializationNimacimab (CB1 inhibitor,…

ByRidhi RastogiMay 19, 2025

Sanofi Reports P-IIa (HS-OBTAIN) Trial Data of Brivekimig for Hidradenitis Suppurativa

Ethris Reports First Patient Dosing in P-IIa Trial of ETH47 for Asthma

Ascletis Pharma Reports First Patient Dosing with ASC30 in P-IIa Trial for Obese or Overweight Patients

Processa Pharmaceuticals and Intact Therapeutics Enter Binding Term Sheet for PCS12852 Licensing Deal

Skye Bioscience Enters a Formulation Development Agreement with Arecor Therapeutics for Nimacimab

Contact US

OUR INFORMATION

FOLLOW US